During the corresponding time, Procept Biorobotics Corporation recorded a revenue increase by 19.93 % year on year, sequentially revenue grew by 8.69 %. While revenue at the Procept Biorobotics Corporation's corporate clients
Procept Biorobotics's Comment on Sales, Marketing and Customers
The company primarily serves urologists in the United States, targeting approximately 2,700 hospitals that perform resective BPH procedures. Its customers include urologists, ambulatory surgery centers, leasing companies, and distribution partners. End customers bill third-party payors, including commercial payors and government agencies, for reimbursement. Medicare provides nationwide coverage for Aquablation therapy for eligible patients, and favorable coverage decisions from many large commercial payors enable access to approximately 95% of men in the U.S. Outside the United States, the company utilizes both direct sales and distribution partners to expand coverage and payment. The company focuses on educating urologists, providing training, and strengthening relationships with key urologists and medical societies to increase adoption of Aquablation therapy.
News about Procept Biorobotics Corporation Contracts
In a significant advancement for prostate cancer treatment, PROCEPT BioRobotics Corporation has received U.S. Food and Drug Administration (FDA) approval to initiate a pivotal randomized clinical study assessing the safety and efficacy of Aquablation therapy in men diagnosed with localized prostate cancer, specifically those categorized within Grade Groups 1 to 3. This promising procedure utilizes a robotic system coupled with high-pressure water jets to ablate prostate tissue, offering a minimally invasive alternative to traditional surgical options.Prostate cancer remains a prevalent concern for men s health, with millions of diagnoses each year in the United States alone. The search for effective treatmen...
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic HyperplasiaData from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy s potential to become the new standard of care in BPH for prostates of all sizes. Additionally, during the corresponding time, Procept Biorobotics Corporation witnessed a remarkable revenue increase of 71.38% year on year, with sequential growth of 5.35% as their corporate clients saw immense benefits. This article explores the implications of these findings and showcases the significance of Aquablation therapy in revolutionizing the treatment of...
Procept Biorobotics’s Comment on Sales, Marketing and Customers
The company primarily serves urologists in the United States, targeting approximately 2,700 hospitals that perform resective BPH procedures. Its customers include urologists, ambulatory surgery centers, leasing companies, and distribution partners. End customers bill third-party payors, including commercial payors and government agencies, for reimbursement. Medicare provides nationwide coverage for Aquablation therapy for eligible patients, and favorable coverage decisions from many large commercial payors enable access to approximately 95% of men in the U.S. Outside the United States, the company utilizes both direct sales and distribution partners to expand coverage and payment. The company focuses on educating urologists, providing training, and strengthening relationships with key urologists and medical societies to increase adoption of Aquablation therapy.
Sources:
Procept Biorobotics Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Procept Biorobotics Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Procept Biorobotics Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
86.82 %